Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.71 |
| ▸ | RAB9A | P51151 | 9/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.61 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.60 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.58 |
| ▸ | DDX3X | O00571 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18788945 | 0.86 | NPC1 (0.67) | NPC1RAB9AKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL9893004 | 0.86 | CSNK2A2 (0.74) | NPC1RAB9AKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL11480689 | 0.84 | CSNK2A2 (0.83) | NPC1RAB9AKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL4459490 | 0.84 | HDAC1 (0.62) | NPC1RAB9AKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL2421423 | 0.83 | KDM4E (0.75) | NPC1RAB9AKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL8144852 | 0.83 | RAB9A (1.00) | NPC1RAB9AKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL231006 | 0.82 | NPC1 (0.63) | NPC1RAB9AKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL16253030 | 0.82 | NPC1 (0.64) | NPC1RAB9AKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL9891908 | 0.82 | NPC1 (0.63) | NPC1RAB9AKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL7929987 | 0.82 | NPC1 (0.63) | NPC1RAB9AKMT2AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710224-B2 | Heterocyclic compounds as CCR2B antagonists | ASTRAZENECA AB (SE) | 2014-04-29 | — | — | US | disclosed |
| US-20120264762-A1 | Heterocyclic Compounds as CCR2 Antagonists | ASTRAZENECA AB (SE) | 2012-10-18 | — | — | US | disclosed |
| US-20090099156-A1 | Heterocyclic Compounds as Ccr2b antagonists | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| EP-1831164-A1 | HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006067401-A1 | HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264762-A1 | Heterocyclic Compounds as CCR2 Antagonists | CCR2, CCR3, CXCR2 | NPC1 1260/4885RAB9A 3914/4885KMT2A 3450/4885 |
| US-20090099156-A1 | Heterocyclic Compounds as Ccr2b antagonists | CCR2, CCR3, CXCR2 | NPC1 1577/4885RAB9A 4032/4885KMT2A 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.